Which care models will handle the scourge of metabolic disorders? Beyond the societal questions raised by this public health phenomenon, the real concern is whether traditional care models are capable of managing this group of conditions effectively and sustainably. This largely because traditional care models are episodic and put little focus on behaviour change that is dearly needed to reverse the trend. Among those who have realized it and are striving for alternatives, Ihsan Almarzooqi and his team at meta[bolic] stand out. Based in Dubai, they have developed and deployed a unique care model, which they aim to replicate in Europe, starting with the UK. Their approach blends cutting-edge diagnostics, remote monitoring, and a care pathway involving frequent interactions with medical staff—enough to drive long-term behavioural change. And its efficacy has been demonstrated through numerous studies published since its inception. Beyond this hybrid care model, what is striking about Ihsan and the meta[bolic] philosophy is their relentless focus on improving outcomes for patients and incorporating the latest care innovations to raise the bar. Up to the point of reducing their operational margin to extend their knowledge of each patient, as long as it improves the level of care. In this episode, we discuss what makes this care pathway unique, its implementation, the results, and how we can leverage traditional reimbursement schemes while still delivering a continuous and outcome-oriented care experience. An inspiring and thought-provoking conversation on what care models for metabolic disorders can be, despite the constraints posed by most health systems! Timeline: 00:00:00 - What led Ihsan to pioneer new care delivery models 00:06:03 - The extent of the metabolic diseases pandemic 00:10:39 - Why traditional care models fail to address metabolic diseases 00:16:49 - The components that make up the meta[bolic] care model 00:23:37 - How the meta[bolic] care model is funded in the UAE 00:30:57 - Ihsan’s philosophy about evidence generation and how it is lived at meta[bolic] 00:33:28 - Scaling the meta[bolic] model to other geographies beyond the UAE 00:38:45 - How to keep patients engaged throughout their care journey 00:41:55 - Ihsan’s wishes for the democratization of value-based care What we also talked about with Ihsan: Continuous glucose monitors (CGMs) GLP-1 agonists Labcorp p-Tau217 VO2 max test PromarkerD test As mentioned by Ihsan during the episode, you can have a read at Ground Truths by Dr. Eric Topol and his recent book Super Agers, an encyclopedia of the latest medical knowledge around longevity. Ihsan also recommends listening to Dr. Peter Attia’s podcast The Drive, which investigates everything from exercise and nutritional biochemistry to cardiovascular health, cancer, cognitive health, mental and emotional well-being, and beyond. You may also read Ihsan’s publication in NEJM Catalyst Innovations in Care Delivery alongside Hala Zakaria, and Ali Hashemi, on their hybrid care model to manage diabetes in the UAE. You can get in touch with Ihsan via LinkedIn, and follow meta[bolic]’s activities on their website, LinkedIn, Facebook, Instagram, and YouTube. ✉️ If you want to give me feedback on the episode or suggest potential guests, contact me over LinkedIn or via email! ⭐️ And if you liked the episode, please share it, subscribe to the podcast, and leave a 5-star review on streaming platforms! 🙏 You can also support my work by doing a PayPal donation @ImpulsePodcast! 👍 Lastly, don’t forget to follow our activities on LinkedIn and our website!

To discover the whole episode, type "#57 - Reimagining care for metabolic disorders - Ihsan Almarzooqi - meta[bolic]" on your preferred streaming platform.

To discover the whole episode, type "#56 - Building the one clinical AI assistant - Ali Parsa - Quadrivia" on your preferred streaming platform.

What will our interactions with our healthcare system look like in the age of AI? Whether you are a patient, a doctor, or any other stakeholder in that system, the question is worth asking. In a world where healthcare costs continue to skyrocket, it is clear we need a radical solution to reverse the trend. The broader challenge is to restore the balance between demand and supply of care, limited by our capacity to train new doctors. Among those relentlessly working on this task are Ali Parsa and his team at Quadrivia. A true veteran of healthcare entrepreneurship, Ali founded Circle Health Group, now the largest chain of private hospitals in the UK, and Babylon Health, the fallen European digital health unicorn that once pioneered the use of AI for remote medicine, symptom checking, and patient triage. Despite all the highs and lows and whatever may have been said about his journey, Ali remains driven by the same mission: making healthcare more accessible and affordable at scale. Today, his efforts are focused on building Qu, which he aims to establish as the gold standard for clinical AI assistants, serving patients, doctors, and the broader ecosystem of actors in the space. In this episode, Ali reveals the inner workings of this formidable tool, showcasing its ability to automate repetitive tasks that healthcare professionals face daily, and the opportunity it offers patients by being available around the clock to advise, educate, and ensure continuous medical supervision. We also discuss the key role of healthcare professionals in the validation of Qu, how to approach the risks and European regulations to make it widely available, and finally, the time and caution required to confidently integrate AI into patients' lives and routine clinical practice. A fascinating conversation that outlines the future of our interactions with the healthcare world! Timeline: 00:00:00 - Ali’s journey as an entrepreneur building healthcare institutions and digital health solutions 00:11:52 - Why healthcare is not affordable nor accessible in the current system 00:16:17 - The interactions where AI will play a crucial role in healthcare (including a demo of Qu!) 00:25:06 - An approach to validate clinically the behaviour of AI in healthcare 00:29:54 - Ali’s observations on the current struggles around AI regulation in healthcare 00:37:22 - Making AI customisable to accommodate different clinical care practices for similar use cases 00:40:01 - Judging a clinical AI’s performance relative to the real performance of healthcare professionals 00:45:10 - Ali’s ambition and Quadrivia’s plans for the next few years What we also talked about with Ali: Special Purpose Acquisition Company (SPAC) Bakul Patel FDA Lovable Modality Partnership We cited with Ali some of the past episodes of the series: #47 - Pushing responsible AI in health - Dr. Ricardo Baptista Leite - HealthAI As mentioned by Ali during the episode, you can have a read at Thinking Machines Lab’s publication “Defeating Nondeterminism in LLM Inference” from September 2025, to dive deep into the nondeterminism problem around the use of LLMs. You can get in touch with Ali via LinkedIn, and follow Quadrivia’s activities on their website and on LinkedIn. ✉️ If you want to give me feedback on the episode or suggest potential guests, contact me over LinkedIn or via email! ⭐️ And if you liked the episode, please share it, subscribe to the podcast, and leave a 5-star review on streaming platforms! 🙏 You can also support my work by doing a PayPal donation @ImpulsePodcast! 👍 Lastly, don’t forget to follow our activities on LinkedIn and our website!

Do you know how organs are traditionally transported for transplantation purposes? In a cooler filled with ice. When I learned that this approach was the most widespread method, I admit I was quite shocked... We talk here about "living" organs whose preservation is crucial for the success of their transplant! And as you can imagine, these transplants are often vital. The good news is: some people have racked their brains and rolled up their sleeves to change all that! And one of them is none other than Lisa Anderson, Co-Founder and President of Paragonix Technologies. With her team, she has literally redefined how organs could be transported, wiping the slate clean of an archaic, despite standard method. Last year, their technology was named one of TIME’s 200 Best Inventions in the Medical Care category. A technology that allows organs to be preserved and monitored under ideal conditions of temperature, pressure, and perfusion. Since its creation in 2010, the company has enabled the transport of over 10,000 hearts, lungs, kidneys, livers, and pancreases combined to date. A paradigm shift, which not only allows for better preservation of these tissues during transport but is also accompanied by a surprising improvement in transplant outcomes, and helps democratise access to them. We talk about all of this with Lisa, from the complexity of developing such a system to the change management required to lead to its acceptance in the medical field. And everything that this changes for the patients who benefit from it every day. A conversation that dusts off a long-established medical practice and lifts the veil on a unique MedTech success story! Timeline: 00:00:00 - How Lisa got into the transplantation and organ transportation space 00:05:54 - The criticality of organ preservation before a graft 00:08:27 - The parameters to control when transporting organs 00:11:38 - The benefits of improved organ preservation on graft success 00:19:01 - Paragonix Technologies’ clients and commercial models 00:21:20 - Sustainability considerations in the organ transportation business 00:25:29 - Paragonix Technologies’ plans for geographic expansion 00:28:00 - The journey from A to Z of an organ between its donor and recipient 00:30:56 - Changing practices and mindsets around organ transportation 00:33:20 - The engineering challenges around the creation of Paragonix Technologies’ first products 00:40:07 - Matching better the demand and supply of organ transplants What we also talked about with Lisa: Getinge As mentioned by Lisa during the episode, you can have a read at Paragonix Technologies’ latest publications here and find out more about their products and technology on their website. You can get in touch with Lisa via LinkedIn, and follow Paragonix Technologies’ activities on LinkedIn, X, Facebook, and YouTube. ✉️ If you want to give me feedback on the episode or suggest potential guests, contact me over LinkedIn or via email! ⭐️ And if you liked the episode, please share it, subscribe to the podcast, and leave a 5-star review on streaming platforms! 🙏 You can also support my work by doing a PayPal donation @ImpulsePodcast! 👍 Lastly, don’t forget to follow our activities on LinkedIn and our website!

To discover the whole episode, type "#55 - Reinventing organ transportation - Lisa Anderson - Paragonix Technologies" on your preferred streaming platform.

While studies have yet to prove a direct causal link, the correlation between smartphone use and declining mental health is well-established, a trend especially concerning among young people. But what if the same technology contributing to the problem could also be the solution? It turns out the therapeutic potential of our smartphones for mental health is no longer up for debate, and one company at the forefront of this revolution is HelloBetter. In this episode, we dive into the fascinating world of digital cognitive behavioural therapy with Hannes Klöpper, its Co-Founder and CEO. Hannes breaks down how his team developed one of the world's most extensive portfolios of digital mental health therapies, covering conditions from depression and burnout to panic attacks and vaginismus. These treatments demonstrate how digital-first solutions can be remarkably effective, prescribable by healthcare professionals, and accessible anytime, anywhere. We also explore the game-changing potential of AI and Large Language Models (LLMs) in mental health, and how they are opening new frontiers for preventing and detecting mental health symptoms early! Timeline: 00:00:00 - What drew Hannes to the cause of HelloBetter 00:05:55 - The power of delivering cognitive behavioural therapy through a smartphone 00:11:50 - How HelloBetter supports patients as an intervention for mental health distress 00:16:20 - The mental health conditions for which HelloBetter provides digital therapeutic programs 00:20:24 - How the therapeutic performance of HelloBetter’s programs is evaluated 00:25:39 - The duality of smartphones as vectors of mental illnesses and vehicles for their treatment. 00:28:54 - What AI and LLMs change for mental health care 00:39:15 - How Hannes keeps his own mental health in check What we also talked about with Hannes: Vaginismus Panic attacks ChatGPT Technical University of Munich Stanford University As mentioned by Hannes during the episode, you can have a read at Exits & Outcomes, Second Opinion, and Healthtech Off The Record, three newsletters that provide in-depth insights and news about the healthtech business. You can get in touch with Hannes via LinkedIn, and follow HelloBetter’s activities on their website, LinkedIn, X, Instagram, and Facebook. ✉️ If you want to give me feedback on the episode or suggest potential guests, contact me over LinkedIn or via email! ⭐️ And if you liked the episode, please share it, subscribe to the podcast, and leave a 5-star review on streaming platforms! 🙏 You can also support my work by doing a PayPal donation @ImpulsePodcast! 👍 Lastly, don’t forget to follow our activities on LinkedIn and our website!

To discover the whole episode, type "#54 - Making the smartphone a psychiatrist - Hannes Klöpper - HelloBetter" on your preferred streaming platform.

Is there a future where we will manufacture entire organs? If that's the case, it’s not tomorrow. Yet, the era of regenerative medicine and tissue engineering is very much real and happening now! In some fields, like in dentistry, we are already 3D printing implants that are placed in patients' mouths. In others, like in orthopedic or plastic surgery, cells are harvested from patients to be modified and placed back into their bodies. But what we can't do yet is create complex, functional tissue constructs that can actively remodel and integrate with the human body to restore physiological function. This is the challenge that Simon Mackenzie and his team at Cellbricks Therapeutics are striving to overcome. The technology they have developed is fascinating, sitting at the crossroads of biomaterials, cellular engineering, and 3D printing. A discipline that aims to create the first "tissue therapeutics." The prospects it opens up are incredible: building grafts to heal complex wounds, functional implants for the liver, pancreatic islets for insulin production, and much more! In this episode, we explore the inner workings of this fascinating field and the road ahead before the first tissue therapeutics are used routinely in the clinic, from a technical and regulatory perspective. A thought-provoking conversation offering a glimpse into what a truly "regenerative" medicine could look like in the future! Timeline: 00:00:00 - Simon’s background as a Biochemist and seasoned executive in the life sciences industry 00:08:28 - Defining bioprinting, biofabrication, and tissue therapeutics 00:12:56 - Cellbricks’ mission to recover tissue loss thanks to engineered tissue therapeutics 00:20:52 - Current evidence on the therapeutic potential of biofabricated tissues 00:24:55 - Cellbricks’ biofabrication platform to engineer living tissues 00:30:33 - The challenges around the transport of biofabricated tissues 00:35:36 - The path toward broad use of biofabricated tissues in medicine What we also talked about with Simon: Erik Gatenholm Cellink BICO Aspect Biosystems Daniela Marino Cutiss Organoids L’Oréal Lisa Anderson Paragonix Technologies As suggested by Simon during the episode, you can learn more about biofabrication and tissue engineering on the Advanced Regenerative Manufacturing Institute website. You can get in touch with Simon via LinkedIn, and follow Cellbricks Therapeutics’ activities on their website, and LinkedIn. ✉️ If you want to give me feedback on the episode or suggest potential guests, contact me over LinkedIn or via email! ⭐️ And if you liked the episode, please share it, subscribe to the podcast, and leave a 5-star review on streaming platforms! 🙏 You can also support my work by doing a PayPal donation @ImpulsePodcast! 👍 Lastly, don’t forget to follow our activities on LinkedIn and our website!

To discover the whole episode, type "#53 - Engineering living tissue therapeutics - Simon Mackenzie - Cellbricks Therapeutics" on your preferred streaming platform.

Is there a simple way to know your hydration level? Not really. It's a surprising reality, considering our bodies are composed of roughly 60% water. When you consider that half of all people drink less than recommended and that chronic dehydration leads to an increased risk of chronic diseases and premature mortality, it becomes clear that monitoring this parameter daily is a public health imperative. The good news is that Mark Kendall and his team at WearOptimo have developed a technology that could be a game-changer. It's a wearable sensor, similar to a continuous glucose monitoring (CGM) patch, capable of continuously and non-invasively measuring our body's water content at any given moment—a technological feat that relies on one of our largest water reservoirs: our skin. In this episode, we unpack how Mark and his team developed this sensor and explore the science behind how it works. We discuss what this could change for our understanding of human physiology, not only in extreme situations for elite athletes but, more importantly, in our everyday lives. Join us for an episode on the fundamental role of water in the body, the skin's critical role in its regulation, and the window of opportunity this organ opens for sensing other essential molecules right from its surface! Timeline: 00:00:00 - Mark’s journey as a biomedical engineer creating technologies for drug delivery and sensing through the skin 00:05:10 - The dehydration pandemic and the opportunity around hydration sensing 00:12:34 - Building a skin patch to monitor hydration levels with clinical-grade precision and no needle 00:22:47 - Relevant use cases for the WearOptimo sensor and complementarity with other wearables 00:25:40 - Going toward one wearable platform to measure multiple biomarkers at once 00:27:20 - The next steps for WearOptimo and scaling up its commercialisation efforts 00:29:55 - Working alongside ex-Formula 1 driver Mark Webber to understand hydration in elite athletes 00:34:10 - Mark’s tips and tricks to stay hydrated What we also talked about with Mark: Gates Foundation Nanopatch Continuous Glucose Monitoring Whole-body impedance Formula 1 Mark Webber Oscar Piastri Prof. Robert Langer Moderna We mentioned with Mark some of the past episodes of the series: #39 - Crafting the best connected health experience - Matthieu Menanteau - Withings #23 - Disrupting the smart wearables industry - Leo Grünstein - Spiden #11 - Turning the lab into a wearable platform - Esmeralda Megally - Xsensio As suggested by Mark during the episode, you can learn more about the long-term health outcomes associated with hydration status by reading the paper from Natalia I. Dmitrieva et al. published in Nature Reviews Nephrology in 2024. You can also watch Mark’s TED Talk about the Nanopatch, the needle-free immunisation technology that he pioneered, on YouTube. You can get in touch with Mark via LinkedIn, and follow WearOptimo’s activities on their website, LinkedIn, and X. ✉️ If you want to give me feedback on the episode or suggest potential guests, contact me over LinkedIn or via email! ⭐️ And if you liked the episode, please share it, subscribe to the podcast, and leave a 5-star review on streaming platforms! 🙏 You can also support my work by doing a PayPal donation @ImpulsePodcast! 👍 Lastly, don’t forget to follow our activities on LinkedIn and our website!

To discover the whole episode, type "#52 - Sensing hydration through the skin - Mark Kendall - WearOptimo" on your preferred streaming platform.

Three years after the 2022 "crypto winter" severely damaged public confidence in these technologies (even among healthcare leaders), the term Web3 is conspicuously absent from the current healthtech space. So, what happened? And where do we really stand with the adoption of these technologies within our healthcare systems? Anca Petre is perfectly positioned to give us answers. A trained pharmacist, she has been exploring Web3 and its healthcare applications for over eight years, speaking on the international stage to educate and share key insights on using these technologies to improve health outcomes. Her assessment is stark: while the core value proposition of Web3 in health remains intact—offering breakthroughs in traceability, security, and patient control over data—its adoption by key players is still marginal. In this episode, Anca shares her analysis of the current landscape, her belief in the untapped potential of these technologies, and a preview of what tomorrow's medical research could look like, powered by decentralised science. Tune in for a conversation with a true health geek, one with her feet firmly planted in the realities of today's systems! Timeline: 00:00:00 - Anca’s journey at the interface of healthcare, Web3, and content creation 00:04:14 - Today’s value proposition and use cases for Web3 in healthcare 00:07:02 - Why we hear less about Web3 in healthcare these days 00:13:51 - Making the Web3 user experience flawless in healthcare 00:16:50 - Where Web3 did not live up to its promises in healthcare 00:18:32 - The interplays of Web3 and AI in healthcare 00:24:39 - Healthcare innovation and its dependencies on systemic changes 00:33:49 - Paving a new way for medical research with decentralised science What we also talked about with Anca: Jim Nasr MedShake Studio ChatGPT Metaverse NFTs Decentralised Autonomous Organisation (DAO) DeSci Nordics We cited with Anca some of the past episodes of the series: #10 - Applying blockchain technology to healthcare - Eberhard Scheuer - dHealth Foundation As suggested by Anca during the episode, you can learn more about Web3 and its applications in healthcare through the podcast Tech Anatomy that she is hosting and producing. For further information on the topic, she recommends consulting IEEE.org, following Allie K. Miller’s work, and looking at Molecule.xyz in case you want to dive deeper into decentralised science. You can follow Anca’s activities on LinkedIn, X, and YouTube, and discover the other podcasts she is producing for healthcare clients with MedShake Studio! ✉️ If you want to give me feedback on the episode or suggest potential guests, contact me over LinkedIn or via email! ⭐️ And if you liked the episode, please share it, subscribe to the podcast, and leave a 5-star review on streaming platforms! 🙏 You can also support my work by doing a PayPal donation @ImpulsePodcast! 👍 Lastly, don’t forget to follow our activities on LinkedIn and our website!

To discover the whole episode, type "#51 - Bridging web3 and healthcare - Anca Petre - Tech Anatomy" on your preferred streaming platform.

What's the link between quantum physics, AI, and drug discovery? Maximilien Levesque might be the perfect person to answer. A former theoretical physicist, he realised his research could transform drug development by fundamentally understanding how molecules interact at the atomic level. In 2019, he co-founded Aqemia with Emmanuelle Martiano Rolland to turn that vision into reality. Their mission is bold: to design new molecules, atom by atom, capable of binding "undruggable" therapeutic targets. Unlike AI models that base themselves on existing compounds, Aqemia's generative engine creates novel structures, opening up a new universe of possibilities. In this episode, Maximilien pulls back the curtain on one of TechBio's most promising startups. With passion and clarity, he breaks down their approach to drug design, explaining how these "digitally-native" compounds go from the numeric world to real-world testing. A conversation to understand the ins and outs of an ongoing revolution in the pharmaceutical industry! Timeline: 00:00:00 - Maximilien’s background as a researcher in mathematics and quantum physics 00:03:46 - What drew Maximilien to drug discovery 00:05:43 - The link between quantum physics and drug discovery 00:10:27 - Aqemia’s technology to design new molecules atom-by-atom 00:18:36 - Aqemia’s pipeline and ongoing preclinical programs 00:20:27 - The difference between AI-based drug discovery and physics-based drug discovery 00:27:55 - Striking a balance between internal development programs and external collaborations 00:32:35 - Aqemia’s approach to talent recruitment at the interface of biology, mathematics, and computer science 00:34:23 - Maximilien’s wish to enter clinical trials in 2026 What we also talked about with Maximilien: HIMSS Europe École Normale Supérieur (ENS) Centre National de la Recherche Scientifique (CNRS) Commissariat à l’Énergie Atomique et aux Énergies Alternatives (CEA) Ornstein-Zernike equation American Institute of Physics Sanofi Institut Gustave Roussy We cited with Maximilien some of the past episodes of the series: #40 - Cracking biology through AI - JP Vert - Owkin #33 - Building the next TechBio venture - Mati Gill - AION Labs #13 - Catalyzing drug discovery using organ-on-a-chip models - Bas Trietsch - Mimetas You can learn more about Maximilien’s publications here and prompt ChatGPT, as he suggested, to find out more about quantum physics, AI, and their applications in the field of drug discovery! You can reach out to Maximilien via LinkedIn and follow Aqemia’s activities on their website and LinkedIn page! ✉️ If you want to give me feedback on the episode or suggest potential guests, contact me over LinkedIn or via email! ⭐️ And if you liked the episode, please share it, subscribe to the podcast, and leave a 5-star review on streaming platforms! 🙏 You can also support my work by doing a PayPal donation @ImpulsePodcast! 👍 Lastly, don’t forget to follow our activities on LinkedIn and our website!

To discover the whole episode, type "#50 - Scaling drug discovery with quantum physics and AI - Maximilien Levesque - Aqemia" on your preferred streaming platform.

Can we learn from extreme cancer survivors to develop new treatments? This is the bet that Nicolas Wolikow and his team at Cure51 are making. Backed by the world's top cancer centers and specialists, they work around the clock to build the largest-ever health dataset of patients who defied the odds—people diagnosed with stage 4 cancer who were given a few months to live, yet survived more than five years. The goal is to understand what makes their biology unique and what characterises their incredible response to the treatments they received. A unique approach to identify new therapeutic targets and enrich our arsenal against a disease whose incidence continues to grow day by day. In this episode, Nicolas lifts the veil on the rigorous method they follow to achieve this feat, from the collection of clinical and multi-omics data to the identification of these targets and their validation in clinical trials. A method to reverse-engineer cancer survival, founded on the latest progress in computational biology, and whose success depends on the close collaboration between patients, hospitals, and industrial partners! Timeline: 00:00:00 - Nicolas’ background as an entrepreneur at the interface of healthcare, technology, and digital innovation 00:06:45 - Understanding the mechanisms behind cancer thanks to exceptional survivors 00:10:24 - Stories of patients in full remission after a stage 4 cancer diagnosis 00:12:21 - Building the platform to host the largest dataset of cancer survivors ever made 00:14:36 - Making sense of the survivors’ data to identify underlying biological mechanisms 00:19:28 - Early findings and novel therapeutic targets investigated so far 00:28:18 - The economic model behind Cure51 00:30:45 - Convincing hospitals and health systems to join Cure51’s mission What we also talked about with Nicolas: HLTH Europe Cancer stages Chemotherapy Rosalind Franklin Variant.bio We cited with Nicolas some of the past episodes of the series: #40 - Cracking biology through AI - JP Vert - Owkin As Nicolas mentioned during the episode, you can learn more about Cure51’s activities on their website, and follow their latest news on LinkedIn, Instagram, and Facebook. You can reach out to Nicolas via LinkedIn and find more details about the ROSALIND study in this abstract. To hear Camille Moses’ incredible story as a cancer survivor, we invite you to listen to her testimonial on the Project Purple podcast. ✉️ If you want to give me feedback on the episode or suggest potential guests, contact me over LinkedIn or via email! ⭐️ And if you liked the episode, please share it, subscribe to the podcast, and leave a 5-star review on streaming platforms! 🙏 You can also support my work by doing a PayPal donation @ImpulsePodcast! 👍 Lastly, don’t forget to follow our activities on LinkedIn and our website!

To discover the whole episode, type "#49 - Reverse-engineering cancer survival - Nicolas Wolikow - Cure51" on your preferred streaming platform.

Disclaimer: Blythe and I both work for Roche; nevertheless, all opinions expressed in this episode are our own and do not necessarily represent the position of our employer. What's really behind the term "real-world data" in clinical science? And what can it actually be used for? I asked Blythe Adamson of Flatiron Health to find out the answer. It turns out real-world data is all the medical data collected in the “real world”, meaning outside of any clinical trial. In other words, it's the vast majority of medical data that exists. This includes everything from the results of blood tests, scans, and vaccinations to doctors' handwritten notes. While the idea of using it to develop new treatments seems obvious, the reality is far from simple. Because access to this data is disparate and varies from one country to another. Because the diversity of their modality renders their interpretation complex. And because until recently, we did not have the computational tools to make it work. But now, in the age of AI and mass digitalisation of healthcare, all of this is changing at lightning speed. Drawing on her expertise at the intersection of epidemiology, data science, and health policy, Blythe walks us through the immense challenges and opportunities of real-world data, and how they are poised to revolutionise the development of tomorrow's therapies. An episode to understand precision medicine and the central role of real-world evidence! Timeline: 00:00:00 - Blythe’s background at the interface of epidemiology, data science, and health policy 00:09:33 - The power of real-world data in medicine and drug development 00:17:11 - The barriers to accessing and leveraging real-world data at scale 00:20:26 - Two examples where AI can help make sense of real-world data 00:25:46 - Traditionally overlooked real-world data modalities in medicine 00:27:52 - Breaking down language barriers across real-world datasets 00:35:10 - Some predictions on the next AI-driven breakthroughs in oncology What we also talked about with Blythe: Operation Warp Speed Resilience Patient-Reported Outcome Measures (PROMs) Trusted Research Environments De-identification American Society of Clinical Oncology (ASCO) Circulating tumor DNA (ctDNA) American Heart Association European Society of Cardiology We cited with Blythe some of the past episodes of the series: #40 - Cracking biology through AI - JP Vert - Owkin As Blythe mentioned during the episode, you can visit her blog at blytheadamson.com for more information about her work. The book recommended by Blythe is Spillover: Animal Infections and the Next Human Pandemic by David Quammen. You can get in touch with Blythe via LinkedIn, and follow the activities of Flatiron Health on LinkedIn, X, and Instagram. ✉️ If you want to give me feedback on the episode or suggest potential guests, contact me over LinkedIn or via email! ⭐️ And if you liked the episode, please share it, subscribe to the podcast, and leave a 5-star review on streaming platforms! 🙏 You can also support my work by doing a PayPal donation @ImpulsePodcast! 👍 Lastly, don’t forget to follow our activities on LinkedIn and our website!

To discover the whole episode, type "#48 - Driving precision medicine with real-world data - Blythe Adamson - Flatiron Health" on your preferred streaming platform.